Clinical Trials
206 trialsA Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
A Study of PHST001 in Advanced Solid Tumors
Pheast Therapeutics
A Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors
Health Hope Pharma
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Astellas Pharma Inc
PIKASSO-01
Eli Lilly and Company
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
LuCa-MERIT-1
BioNTech SE
Study of INCB123667 in Subjects With Advanced Solid Tumors
Incyte Corporation
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Amgen
MUIR
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
MK-3475A-C18
Merck Sharp & Dohme LLC
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
SillaJen, Inc.
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors
HC Biopharma Inc.
A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
RemeGen Co., Ltd.
A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
BeOne Medicines
Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies
Regeneron Pharmaceuticals
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer
HC Biopharma Inc.
Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer
Beijing Wehand-Bio Pharmaceutical Co., Ltd
DB-08
AstraZeneca
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
AbbVie
MICA
Cullinan Therapeutics Inc.
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
Enliven Therapeutics
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
MK-4830-001
Merck Sharp & Dohme LLC
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
P102
Leap Therapeutics, Inc.
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology Inc.
MK-0482-001
Merck Sharp & Dohme LLC
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
A Study of TXN10128 in Subjects With Solid Tumors
Txinno Bioscience Inc.
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
AstraZeneca
FORTITUDE-201
Amgen
First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
Onward Therapeutics
A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients
Health Hope Pharma
AN0025 and Chemoradiotherapy Combination in Esophageal Cancer
Adlai Nortye Biopharma Co., Ltd.
Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies
Boehringer Ingelheim
CLOVER
AstraZeneca
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
Genentech, Inc.
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Jazz Pharmaceuticals
IVY
Eli Lilly and Company
A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies
Astellas Pharma Inc
A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Hoffmann-La Roche